Strata Skin Sciences closes direct stock offering
Strata Skin Sciences, Inc. reported that it has closed a previously announced registered direct offering of its common stock.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Strata Skin Sciences, Inc. reported that it has closed a previously announced registered direct offering of its common stock. The company issued and sold 1,097,547 shares of common stock at a purchase price of $2.204 per share, with Ladenburg Thalmann & Co. Inc. serving as the exclusive placement agent. The transaction details were disclosed in a press release dated September 4, 2025, which is furnished as an exhibit and not deemed filed for liability purposes under the securities laws.
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did STRATA Skin Sciences (SSKN) announce in this 8-K?
The company announced the closing of a previously announced registered direct offering for the issuance and sale of 1,097,547 shares of its common stock at $2.204 per share.
Who acted as placement agent for STRATA Skin Sciences (SSKN) in this deal?
Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for the registered direct offering.
Where can investors find more details about STRATA Skin Sciences' stock offering?
More details are provided in the company’s press release dated September 4, 2025, furnished as Exhibit 99.1 to this report.
Is the press release about STRATA Skin Sciences' offering considered filed with the SEC?
No. The information in Item 7.01, including Exhibit 99.1, is being furnished and is not deemed “filed” or subject to Section 18 liabilities.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): September 4, 2025
(Exact Name of Registrant Specified in Charter)
|
|
|
|
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
|
|
|
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant's telephone number, including area code: 215 -619-3200
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
|
| Item 7.01. |
Regulation FD Disclosure.
|
On September 4, 2025, STRATA Skin Sciences, Inc. (the “Company”) issued a press release announcing the
closing of its previously announced registered direct offering for the issuance and sale of 1,097,547 shares of the Company’s common stock at a per share purchase price of $2.204. Ladenburg Thalmann & Co. Inc. acted as exclusive placement
agent for the offering. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information set forth in this item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section
18 of the Securities Exchange Act or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set
forth by specific reference in any such filing.
| Item 9.01. |
Financial Statements and Exhibits.
|
(d) Exhibits.
The following presentation is furnished as an exhibit to this Current Report on Form 8-K and shall not be deemed to be “filed”:
|
Exhibit No.
|
Exhibit Description
|
|
|
99.1
|
Press Release dated September 4, 2025, Issued by Strata Skin Sciences, Inc.
|
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
STRATA SKIN SCIENCES, INC.
|
|||
|
Date: September 4, 2025
|
By:
|
/s/ John Gillings
|
|
|
John Gillings
|
|||
|
Chief Accounting Officer
|
|||